{"url_path":"/sec/aidx/8-k/2026-05-20/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 ** **Results of Operations and Financial Condition****.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-059526-index.html","accession_number":"0001213900-26-059526","cik":"0001139685","ticker":"AIDX","issuer_name":"20/20 Biolabs, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-059526-index.html","primary_entity_key":"0001139685","primary_entity_name":"20/20 Biolabs, Inc."},"word_count":124,"has_tables":true,"body_markdown":"**Item 2.02** **Results of Operations and Financial Condition****.**\n\n \n\nOn May 20, 2026, 20/20 Biolabs, Inc. (the\n“Company”) issued a press release regarding its financial results for the quarter ended March 31, 2026. A copy of the\npress release is furnished as Exhibit 99.1 to this report.\n\n \n\nThe information furnished with this Item 2.02,\nincluding Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,\nas amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing\nunder Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as expressly set forth by specific\nreference in such a filing."}